Candel Therapeutics Inc Share Price Today: Live Updates & Key Insights

Candel Therapeutics Inc share price today is $4.97, up 1.22%. The stock opened at $4.92 against the previous close of $4.91, with an intraday high of $5.17 and low of $4.88.

Candel Therapeutics Inc Share Price Chart

Candel Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Candel Therapeutics Inc Share Price Performance

$4.97 0.0122(1.22%) CADL at 23 Mar 2026 12:21 PM Biotechnology
Lowest Today 4.88
Highest Today 5.17
Today’s Open 4.92
Prev. Close 4.91
52 Week High 8.69
52 Week Low 4.25
Day’s Range: Low 4.88 High 5.17
52-Week Range: Low 4.25 High 8.69
1 day return -
1 Week return -0.5
1 month return -
3 month return -16.31
6 month return -5.05
1 year return -42.58
3 year return +257.91
5 year return -29.43
10 year return -

Candel Therapeutics Inc Institutional Holdings

FMR Inc 11.24

Fidelity Select Biotechnology 7.57

BlackRock Inc 3.25

Vanguard Group Inc 3.15

Portolan Capital Management, LLC 2.31

Vanguard Total Stock Mkt Idx Inv 1.88

Fidelity Growth Compy Commingled Pl S 1.71

Strategic Advisers U.S. Total Stock 1.51

iShares Russell 2000 ETF 1.43

Geode Capital Management, LLC 1.33

Fidelity Growth Company Fund 1.23

Halter Ferguson Financial Inc 1.02

State Street Corp 0.94

Fidelity Small Cap Index 0.58

BANOR SICAV Rosemary S EUR Acc 0.56

Vanguard Institutional Extnd Mkt Idx Tr 0.56

Sands Capital Ventures, LLC 0.55

iShares Russell 2000 Growth ETF 0.45

iShares Biotechnology ETF 0.42

Northern Trust Corp 0.42

Fidelity Growth Company K6 0.37

Fidelity Series Growth Company 0.36

State St Russell Sm/Mid Cp® Indx SL Cl I 0.35

Citadel Advisors Llc 0.31

Vanguard Russell 2000 ETF 0.28

Fidelity Extended Market Index 0.28

Tanager Wealth Management LLP 0.27

SSgA Russell Small Cap Completeness Idx 0.23

Aesculape SRI IC 0.22

Susquehanna International Group, LLP 0.19

Charles Schwab Investment Management Inc 0.17

State St Russell Sm Cap® Indx SL Cl I 0.16

iShares Micro-Cap ETF 0.16

Two Sigma Investments LLC 0.14

Bank of New York Mellon Corp 0.13

UBS Group AG 0.13

Nuveen, LLC 0.13

Commonwealth Equity Services Inc 0.11

Kovitz Investment Group Partners, LLC 0.11

Morgan Stanley - Brokerage Accounts 0.10

Candel Therapeutics Inc Market Status

Strong Buy: 3

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Candel Therapeutics Inc Fundamentals

Market Cap 364.04 M

PB Ratio 7.0253

PE Ratio 0.0

Enterprise Value 294.07 M

Total Assets 125.20 M

Volume 1652341

Candel Therapeutics Inc Company Financials

Annual Revenue FY23:31000 0.0M, FY22:125000 0.1M, FY21:125000 0.1M, FY20:125000 0.1M, FY19:125000 0.1M

Annual Profit FY23:null 0.0M, FY22:125000 0.1M, FY21:125000 0.1M, FY20:125000 0.1M, FY19:125000 0.1M

Annual Net worth FY23:-31927000 -31.9M, FY22:-2866000 -2.9M, FY21:-36124000 -36.1M, FY20:-22174000 -22.2M, FY19:-8014000 -8.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-195000 -0.2M, Q2/2025:-242000 -0.2M, Q1/2025:-245000 -0.2M, Q3/2024:null 0.0M, Q2/2024:-249000 -0.2M

Quarterly Net worth Q3/2025:-11269000 -11.3M, Q2/2025:-4796000 -4.8M, Q1/2025:7379000 7.4M, Q3/2024:-10646000 -10.6M, Q2/2024:-22237000 -22.2M

About Candel Therapeutics Inc & investment objective

Company Information Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Organisation Biotechnology

Employees 55

Industry Biotechnology

CEO Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Candel Therapeutics Inc FAQs

What is the share price of Candel Therapeutics Inc today?

The current share price of Candel Therapeutics Inc is $4.97.

Can I buy Candel Therapeutics Inc shares in India?

Yes, Indian investors can buy Candel Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Candel Therapeutics Inc shares in India?

You can easily invest in Candel Therapeutics Inc shares from India by:

Can I buy fractional shares of Candel Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Candel Therapeutics Inc?

Candel Therapeutics Inc has a market cap of $364.04 M.

In which sector does Candel Therapeutics Inc belong?

Candel Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Candel Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Candel Therapeutics Inc?

The PE ratio of Candel Therapeutics Inc is N/A and the PB ratio is 7.03.